Blog

Armando Orlandi: ASCO25 Breast Cancer Update, Early Data from May 30th Session

Armando Orlandi/photos.asco.org

Jun 1, 2025, 11:07

Armando Orlandi: ASCO25 Breast Cancer Update, Early Data from May 30th Session

Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on LinkedIn:

“ASCO25 Breast Cancer Update: Early Data from May 30th Session.

Several preliminary studies presented today warrant careful consideration, though longer follow-up and larger cohorts will be essential for validation:

EMERGING TARGETED APPROACHES:

PF-07248144 (KAT6 inhibitor): Early signals with 37.2% ORR in ER+/HER2- mBC post-CDK4/6i – preliminary data supporting Phase 3 initiation.

Sac-TMT (TROP2 ADC): Initial first-line results showing 70.7% ORR in a/mTNBC – requires validation in larger randomized studies.

Trastuzumab-pkrb + gedatolisib: Early efficacy (43.2% ORR) in heavily pretreated HER2+ mBC with PIK3CA mutations – small cohort data.

INTRACRANIAL ACTIVITY SIGNALS:

SHR-A1811: Early intracranial activity data (84.4% ORR monotherapy, 72.7% + bevacizumab) in small HER2+ brain mets cohort – promising but needs mature survival data.

Adebrelimab + bevacizumab + cisplatin/carboplatin: Preliminary CNS activity (77.1% ORR) in TNBC brain mets – encouraging initial OS trends require longer observation.

TREATMENT OPTIMIZATION INSIGHTS:

Ribociclib + trastuzumab + letrozole: Early first-line data (30.4-month mPFS) suggests potential for chemotherapy-sparing approaches in HR+/HER2+ disease – single-arm study limitations.

Trastuzumab deruxtecan rechallenge: Real-world safety data supports clinical practice after G1 ILD – though patient selection remains critical.

DIAGNOSTIC & DISPARITIES CONSIDERATIONS:

AI-assisted HER2 pathology: Initial training improvements in HER2-low/ultralow scoring accuracy – implementation challenges remain.

HER2+ ADC outcome disparities: Real-world data confirms persistent racial gaps (Asian 89.5% vs Black 80.9% 5-year survival) – systematic barriers need addressing.

While these early results show promise, definitive conclusions await mature data, randomized comparisons, and broader validation. The preliminary nature of many findings underscores the need for continued investigation.

This session exemplifies the iterative nature of oncological research – each data point, however early, contributes to our evolving understanding. The continuous progression from bench to bedside, through phases of clinical development, reflects the relentless pursuit of better outcomes that defines our field.

Today’s preliminary signals may become tomorrow’s standard of care, but only through rigorous validation and the collective effort of the global research community.”

Orlandi summarized early findings from May 30th’s ASCO25 breast cancer session, noting promising yet preliminary results in targeted treatments, CNS activity, and disparities, emphasizing the importance of continued clinical validation.

More posts featuring Armando Orlandi.

Adebrelimab Agostino Gemelli University Hospital Foundation IRCCS Armando Orlandi ASCO25 Bevacizumab Breast Cancer cancer carboplatin CDK4/6i chemotherapy Cisplatin ER fight against cancer G1 ILD gedatolisib Global fight against cancer HER2 HER2 pathology KAT6 inhibitor letrozole MBC monotherapy mTNBC OncoDaily Oncology PF-07248144 PIK3CA Ribociclib SHR-A1811 trastuzumab Trastuzumab deruxtecan TROP2 ADC

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment

15 Posts Not to Miss from the 2nd Day of ASCO 2025

15 Posts Not to Miss from the 1st Day of ASCO 2025

Wafik El-Deiry: Inside Yvonne Award Ceremony 2025